Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s... Read more

Thermo Fisher Scientific to Hold Earnings Conference Call on Monday, February 1, 2021

Thermo Fisher Scientific to Hold Earnings Conference Call on Monday, February 1, 2021 WALTHAM, Mass., Jan. 5, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2020 before the market opens on Monday, February 1,... Read more

Bruker and Evosep Announce Major Progress in Unbiased, Quantitative True Single-cell Proteomics

Breakthrough new paper by Mann-group demonstrates that unbiased, quantitative true single-cell proteomics can address important questions in cell biology and single-cell pathobiology Measured single-cell protein and RNA levels are very different, which implies distinct RNA and protein abundance regulation mechanisms. Protein measurements thus yield complementary quantitative biology information. Results also imply stable cellular core proteomes... Read more

Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer

Basel, 5 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung... Read more

HORIBA Scientific Completes Healthy Business Certification

01/04/2021 NJBIA Certifies HORIBA NJ Office as a Certified Site for Infectious Disease Prevention Piscataway, NJ – January 4th, 2021  HORIBA Scientific, global leader in measurement and analysis solutions for research and industry, is proud to announce that the Piscataway, New Jersey office has completed the requirements of the NJBIA program to achieve the Healthy Business... Read more

HORIBA Participates in a Project to Analyze Samples Collected from Asteroid Ryugu by Asteroid Explorer Hayabusa2

01/04/2021 |   Press Release HORIBA TECHNO SERVICE CO, LTD (Hereinafter HORIBA TECHNO SERVICE) will participate in a project for the initial analysis of samples, including sand and gravel, that the Japan Aerospace Exploration Agency’s (JAXA’s) asteroid explorer Hayabusa2 has collected from the asteroid Ryugu. Six international teams will perform the initial analysis of the samples from Ryugu. Belonging to... Read more

Teledyne to Acquire FLIR Systems

January 4, 2021 ​Cash and Stock Transaction Valued at Approximately $8.0 Billion​ Teledyne and FLIR to Host Joint Conference Call and Webcast at 11:00 a.m. Eastern Today THOUSAND OAKS, Calif. and ARLINGTON, Va. – January 4, 2021 – Teledyne Technologies Incorporated (NYSE:TDY) (“Teledyne”) and FLIR Systems, Inc. (NASDAQ:FLIR) (“FLIR”) jointly announced today that they have... Read more

Bruker Introduces MBT Sepsityper® Kit US IVD for Rapid and Affordable Identification of over 400 Microorganisms from Positive Blood Cultures

MBT Sepsityper Kit US IVD enables rapid, specific detection of many cases of bacteremia-induced sepsis to assist infectious disease specialists in potentially life-saving decisions Used for MALDI Biotyper® (MBT) identification directly from Positive Blood Cultures (PBC) with short time-to-result (TTR) of less than 30 minutes US FDA clearance received in late December for diagnostic use... Read more